Dean Elterman, MD, on the concept of “first-line interventional therapy” in BPH

In this video, Dean S. Elterman, MD, MSc, FRCSC, gives an overview of the recent European Urology Focus paper “Reimagining Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Treatment: A New Approach to First-line Interventional Therapy.” Elterman is an associate professor of urology at the University of Toronto in Ontario, Canada.

Transcription:

Please share some key points from this paper.

[Dr] Steve Kaplan and I have come up with a new concept, almost a new category, of BPH treatments. We're calling this first-line interventional therapy, or FIT. The termMISTs [minimally invasive surgical treatments] came out a couple years ago. I introduced a term called T-MISTs or true MISTs. And now, first-line interventional therapy is really this paradigm that bridges the gap between medications and surgery, and it aims to be an effective, minimally invasive treatment that allows for rapid recovery, minimally invasive side effects, and the ability to keep future options open. Really an ideal FIT is going to be something that will be outpatient, that will give a durable, long-lasting outcome, but also really be more patient centered with respect to outcomes. You want something that's going to be easy to have done to you, and also have an easy recovery. And so I think we may ultimately see a shift towards these FITs, where patients are going to want to opt to have these less-invasive treatments done earlier. They're going to be more patient friendly. And I think a lot of the prostate stents—there's about 5 of them that are currently under investigation—these are really what are going to fit into this category of first-line interventional therapies, or FITs.

This transcript was AI generated and edited by human editors for clarity.